Skip to main content
PZ Cormay S.A. logo

PZ Cormay S.A. — Investor Relations & Filings

Ticker · CRM ISIN · PLCMRAY00029 LEI · 2594006HZJ8OSNK56U87 WAR Manufacturing
Open in API
Filings indexed 692 across all filing types
Latest filing 2019-04-14 Board/Management Inform…
Country PL Poland
Listing WAR CRM

About PZ Cormay S.A.

https://cormaydiagnostics.com/

PZ Cormay S.A. is a manufacturer and distributor of in-vitro diagnostic (IVD) solutions for medical laboratories and clinics. The company develops, produces, and sells a comprehensive portfolio of diagnostic reagents, laboratory analyzers, and quality control systems. Its offerings cater to key diagnostic areas, including clinical chemistry, hematology, and immunoassay. Key product lines feature the Accent series of chemistry analyzers, the Auryx immunoassay system, and the Mythic family of hematology analyzers. The company integrates its extensive experience in reagent manufacturing with advanced Swiss hematology technology to provide reliable, high-performance, and cost-effective diagnostic tools to a global network of distributors and healthcare professionals.

Recent filings

Filing Released Lang Actions
Ocena_RN_PZ_Cormay_SprZarz_2018.pdf
Board/Management Information Classification · 99% confidence The document is titled 'Ocena Rady Nadzorczej PZ CORMAY S.A. sprawozdania Zarządu z działalności Spółki za okres od 01 stycznia 2018 roku do 31 grudnia 2018 roku' (Assessment by the Supervisory Board of PZ CORMAY S.A. of the Management Board's report on the Company's activities for the period from January 1, 2018, to December 31, 2018). This document explicitly details the Supervisory Board's review and positive assessment of the Management Board's annual activity report, referencing the auditor's report for the full fiscal year (ending Dec 31, 2018). This content strongly aligns with the scope of an Audit Report / Information (AR), which covers standalone audit reports, applied accounting principles, and results of internal or regulatory stress tests, as it is the formal review/opinion on the annual financial reporting package, distinct from the full 10-K filing itself. Given the focus on the assessment of the annual report and the auditor's opinion, AR is the most appropriate classification.
2019-04-14 Polish
Ocena_RN_PZ_Cormay_SF_2018.pdf
Audit Report / Information Classification · 95% confidence The document is titled "Ocena Rady Nadzorczej PZ CORMAY S.A. sprawozdania finansowego Spółki za okres od dnia 01 stycznia 2018 roku do dnia 31 grudnia 2018 roku" (Assessment by the Supervisory Board of PZ CORMAY S.A. of the Company's financial statement for the period from January 1, 2018, to December 31, 2018). It details the Supervisory Board's review and positive opinion on the annual financial statement, including the income statement, balance sheet, cash flow statement, and statement of changes in equity for the full year 2018. This document is an official assessment/opinion regarding the annual financial results, which aligns closely with the scope of an Audit Report or Information (AR), as it discusses the review of the financial statement and the auditor's report. Since it is the Supervisory Board's assessment of the *full year* financial statement, it is distinct from a quarterly report (IR) or a simple earnings release (ER). It is not the 10-K itself, but the formal review/opinion on the audited annual figures, making 'AR' (Audit Report / Information) the most appropriate fit among the provided options for a document focused on the audit/review outcome of annual financials. FY 2018
2019-04-14 Polish
List_Prezesa_Zarzadu_PZ_Cormay_2018.pdf
Management Reports Classification · 95% confidence The document is a letter from the Management Board of PZ Cormay S.A. to shareholders, presenting the financial results and key information regarding the company's and the Capital Group's activities for the year 2018. It explicitly mentions consolidated revenues, EBITDA loss, net loss, and details significant non-business related write-downs affecting the financial statements. The closing sentence explicitly encourages reading the 'sprawozdanie' (report). Since this document summarizes the full year's performance and provides management commentary on the results, it strongly aligns with the content expected in a Management Discussion and Analysis (MDA) section, which often precedes or is part of the full Annual Report (10-K). However, given the structure (a letter summarizing results and outlook) and the relatively short length (2813 chars), it functions primarily as the Management's explanation of the financial results and business trends, fitting the definition of 'Management Reports' (MDA) better than the comprehensive 10-K itself, especially if the full 10-K is a separate, much larger filing. It is not a mere Earnings Release (ER) as it discusses specific write-downs and strategic projects in detail, nor is it an Audit Report (AR). It is a management commentary on the annual results.
2019-04-14 Polish
Zmiana terminów publikacji jednostkowego oraz skonsolidowanego raportu rocznego za 2018 rok. - Content (PL)
Report Publication Announcement Classification · 98% confidence The document text, originating from PZ Cormay S.A., explicitly states that the management board is changing the publication dates for the consolidated and individual annual reports for the year 2018. It references a previous current report (raport bieżący) and sets new dates for the release of these annual reports. Since the document is not the annual report itself (10-K) but rather an announcement about the timing/schedule of its release, it fits the definition of a Report Publication Announcement (RPA). The document length is very short (869 chars), supporting the 'announcement' classification over the full report classification.
2019-04-11 Polish
Decyzja dotycząca odpisów w sprawozdaniach finansowych za rok obrotowy 2018 - Content (PL)
Management Reports Classification · 99% confidence The document is a formal announcement from the Management Board of PZ Cormay S.A. (Emitent) regarding the results of impairment tests conducted on capitalized development costs for specific analyzers (Equisse, Hermes Senior, etc.) as of December 31, 2018. It explicitly states that due to these tests, the company decided to create provisions (odpisy) in the financial statements for 2018, totaling 19,385 thousand PLN. This action directly impacts the financial results and balance sheet figures for the year 2018. This content relates to the accounting treatment and valuation of assets, which is a core component of an Audit Report or specific accounting disclosure, rather than a full Annual Report (10-K) or a simple Earnings Release (ER). Given the specific focus on impairment testing results and resulting write-downs impacting the financial statements, the most appropriate classification among the provided options is 'Audit Report / Information' (AR), as it details specific accounting results and principles applied to the financial figures, even if it precedes the final audited report.
2019-04-10 Polish
Kontynuowanie negocjacji w sprawie zbycia udziałów Diesse - Content (PL)
Delisting Announcement Classification · 99% confidence The document text is very short (917 characters) and discusses ongoing negotiations regarding the potential sale of shares in a subsidiary (Diesse Diagnostica Senese S.p.A.) by another subsidiary (Orphee SA). It explicitly states that the company will inform about the status of the negotiations by April 30th. This content relates to a significant corporate transaction (potential M&A activity) but is presented as an update on the negotiation process rather than the final agreement or a full report. Since it concerns a potential takeover/merger activity, the most appropriate category is 'M&A Activity' (TAR). However, given the nature of the announcement—an update on ongoing negotiations rather than the final transaction details or a formal filing like a 10-K or a definitive proxy statement—and the fact that it is a brief regulatory update, it could also be considered a general Regulatory Filing (RNS). Given the specific mention of 'transakcji zbycia' (sale transaction) and 'negocjacji' (negotiations) concerning a subsidiary stake, TAR is more specific than RNS. If the negotiations were to conclude, the resulting document would likely be TAR or a related filing. As an update on the process, it fits best under the general umbrella of corporate actions, but TAR is the most relevant specific category for M&A process updates.
2019-03-28 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.